U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. Performance Data
  4. FDA-TRACK: Agency-wide Program Performance
  5. FDA-TRACK: Biosimilar User Fee Act (BsUFA) Performance
  1. FDA-TRACK: Agency-wide Program Performance

FDA-TRACK: Biosimilar User Fee Act (BsUFA) Performance

 

Subscribe to FDA-TRACK Updates

 

FDA-TRACK: Drugs
FDA-TRACK: Biologics
BsUFA Performance Dashboards User Guide
FDA-TRACK Home

The Federal Food, Drug, and Cosmetic Act (the FD&C Act), as amended by the Biosimilar User Fee Amendments of 2022 (BsUFA III), authorizes FDA to assess and collect fees for biosimilar biological products from October 2023 through September 2027. FDA dedicates these fees to expediting the review process for biosimilar biological products, facilitating the development of safe and effective biosimilar products for the American public.

The Biosimilar User Fee Performance Dashboards (BsUFA Dashboards) provide a concise, interactive, and visual presentation of data that is presented in the legislatively mandated FY 2024 BsUFA Performance Report to Congress for the Biosimilar User Fee Act (the Report). The BsUFA Dashboards are not intended to replace the Report and are to be used as a supplemental tool for viewing the data. The BsUFA Dashboards reflect performance on submissions received and actions taken as of September 30, 2024. The BsUFA Dashboards present final performance in meeting BsUFA goals for FY 2023 and preliminary performance for FY 2024. Final BsUFA performance data for FY 2024 will be presented in the FY 2025 BsUFA Report and referenced in updated versions of the BsUFA Dashboards.

FDA-Track icon: BsUFA Biosimilar Applications and Supplements

Biosimilar Applications and Supplements

The Biosimilar Applications and Supplements Dashboard displays current performance relating to the review of:

  • Original Biosimilar Product Applications
  • Resubmitted Original Biosimilar Applications
  • Original Supplemental Biosimilar Biological Product Applications- Category A, B, C, D, E, and F
  • Resubmitted Supplemental Biosimilar Biological Product Applications- Category A, B, C, D, E, and F
  • Manufacturing Supplements Requiring Prior Approval
  • Manufacturing Supplements Not Requiring Prior Approval

Procedural Notifications

The Procedural Notifications Dashboard displays current performance relating to the notification/review of:

  • Receipt and Planned Review Timeline for Original Category A through D Supplements
  • Issues Identified During the Filing Review for Category E and F Supplements
  • Proprietary Names Submitted During Biosimilar Biological Product Development (BPD) Phase and During Application Review
FDA-TRACK: BsUFA Procedural Notifications
FDA-TRACK: BsUFA Procedural Responses

Procedural Responses

The Procedural Responses Dashboard displays current performance relating to the review of/responses to:

  • Major Dispute Resolutions
  • Responses to Clinical Holds
  • Special Protocol Assessments
  • Human Factors Validation Protocol Submissions to INDs
  • Use-Related Risk Analysis Submissions

Meeting Management

The Meeting Management Dashboard displays current performance relating to the response to/issuance of:

  • Biosimilar Initial Advisory Meeting Requests
  • BPD Type 1, 2a, 2b, 3, and 4 Meeting Requests
  • Biosimilar Initial Advisory Meetings Scheduled
  • BPD Type 1, 2a, 2b, 3, and 4 Meetings Scheduled
  • Biosimilar Initial Advisory Written Response
  • BPD Type 2a, and 2b Written Response
  • Preliminary Response for BPD Type 2b, and 3 Meetings
  • Meeting Minutes for All Meeting Types
FDA-TRACK icon: BsUFA Meeting Management

Sign up to receive FDA-TRACK updates

Get regular FDA email updates delivered on this topic to your inbox.

Back to Top